Antivir Chem Chemother
November 2022
Chronic hepatitis B virus (HBV) infection affects 240 to 300 million people worldwide. In the nucleus of infected hepatocytes, the HBV genome is converted to covalently closed circular DNA (cccDNA), which persists and serves as a transcriptional template for viral progeny. Therefore, a long-term cure for chronic HBV infection will require elimination of cccDNA.
View Article and Find Full Text PDFATI-2173 is an active site polymerase inhibitor nucleotide in development as part of a potentially curative regimen for chronic hepatitis B virus (HBV) infection. This study evaluated the safety, tolerability, pharmacokinetics (PK) and antiviral activity of ATI-2173. This was a phase 1b, randomized, double-blind, placebo-controlled trial in treatment-naive adults with chronic HBV infection conducted in the Republic of Moldova and Ukraine (ClinicalTrials.
View Article and Find Full Text PDFInt J Popul Data Sci
December 2020
Introduction: Fetal Alcohol Spectrum Disorder (FASD) is a neurodevelopmental disorder caused by prenatal alcohol exposure (PAE). FASD research is a rapidly growing field that crosses multiple disciplines. To ensure research is relevant and meaningful for people living with FASD, their families, and the broader public there is a need to engage community members in setting priorities for research.
View Article and Find Full Text PDFAlthough soil C sequestration with cover crops (CCs) has been linked with the potential of CCs in climate change mitigation, the long-term usage of CCs on soil C storage and farm-based economics have been widely overlooked. Therefore, in a CC experiment established in 2007 in a temperate humid climate, four CCs and a no-CC control were compared to evaluate their potential to sequester C and provide economic returns. Total amount of plant C added to soil with CCs translated into greater soil organic carbon (SOC) content by 10-20 Mg C ha than the no-CC control across both sites.
View Article and Find Full Text PDFATI-2173 is a novel liver-targeted molecule designed to deliver the 5'-monophosphate of clevudine for the treatment of chronic hepatitis B infection. Unlike other nucleos(t)ides, the active clevudine-5'-triphosphate is a noncompetitive, non-chain-terminating inhibitor of hepatitis B virus (HBV) polymerase that delivers prolonged reduction of viremia in both a woodchuck HBV model and in humans for up to 6 months after cessation of treatment. However, long-term clevudine treatment was found to exhibit reversible skeletal myopathy in a small subset of patients and was subsequently discontinued from development.
View Article and Find Full Text PDF